NCT04737486View on ClinicalTrials.gov

A First-in-Human Study of AV-001 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Covid19-associated ARDSCovid19ARDS
Interventions
DRUG

AV-001

AV-001 (mpaBr) Cl for Injection 2.5 mg/mL

OTHER

Placebo

D-PBS

Trial Locations (1)

45227

Medpace Clinical Pharmacology Unit, Cincinnati

All Listed Sponsors
lead

Vasomune Therapeutics, Inc.

INDUSTRY

NCT04737486 - A First-in-Human Study of AV-001 in Healthy Subjects | Biotech Hunter | Biotech Hunter